CL2025001381A1 - Inhibidor de la fusión de membranas para inhibir virus del sida y su uso farmacéutico. - Google Patents

Inhibidor de la fusión de membranas para inhibir virus del sida y su uso farmacéutico.

Info

Publication number
CL2025001381A1
CL2025001381A1 CL2025001381A CL2025001381A CL2025001381A1 CL 2025001381 A1 CL2025001381 A1 CL 2025001381A1 CL 2025001381 A CL2025001381 A CL 2025001381A CL 2025001381 A CL2025001381 A CL 2025001381A CL 2025001381 A1 CL2025001381 A1 CL 2025001381A1
Authority
CL
Chile
Prior art keywords
membrane fusion
pharmaceutical use
fusion inhibitor
aids virus
inhibit
Prior art date
Application number
CL2025001381A
Other languages
English (en)
Inventor
He Yuxian
Zhu Yuanmei
GENG Xiuzhu
Chong Huihui
Original Assignee
Inst Pathogen Biology Cams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pathogen Biology Cams filed Critical Inst Pathogen Biology Cams
Publication of CL2025001381A1 publication Critical patent/CL2025001381A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona un inhibidor de la fusión de membranas para inhibir el VIH y una cepa farmacorresistente del mismo, un derivado del mismo, una composición farmacéutica del mismo y un uso farmacéutico del mismo.
CL2025001381A 2022-11-11 2025-05-09 Inhibidor de la fusión de membranas para inhibir virus del sida y su uso farmacéutico. CL2025001381A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211410040.4A CN115724919B (zh) 2022-11-11 2022-11-11 强效抑制艾滋病病毒及其耐药毒株的新型膜融合抑制剂及其药物用途

Publications (1)

Publication Number Publication Date
CL2025001381A1 true CL2025001381A1 (es) 2025-10-17

Family

ID=85295247

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001381A CL2025001381A1 (es) 2022-11-11 2025-05-09 Inhibidor de la fusión de membranas para inhibir virus del sida y su uso farmacéutico.

Country Status (7)

Country Link
EP (1) EP4617282A1 (es)
JP (1) JP2025537298A (es)
KR (1) KR20250109218A (es)
CN (1) CN115724919B (es)
AU (1) AU2023378464A1 (es)
CL (1) CL2025001381A1 (es)
WO (1) WO2024099428A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724919B (zh) * 2022-11-11 2023-06-27 中国医学科学院病原生物学研究所 强效抑制艾滋病病毒及其耐药毒株的新型膜融合抑制剂及其药物用途
EP4685153A1 (en) * 2023-03-20 2026-01-28 Henan Genuine Biotech Co., Ltd. Broad-spectrum viral membrane fusion inhibitor, and preparation method therefor and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822849A (zh) * 2003-03-24 2006-08-23 塞阔伊亚药品公司 长效生物活性缀合物
CN102180951B (zh) * 2011-05-03 2012-09-26 中国医学科学院病原生物学研究所 胆固醇修饰的抗hiv多肽药物及其用途
CN102816215B (zh) * 2012-08-08 2014-07-30 中国医学科学院病原生物学研究所 抑制hiv的短小多肽及药物用途
CN111944025B (zh) * 2017-04-18 2022-06-07 中国医学科学院病原生物学研究所 艾滋病病毒膜融合抑制剂脂肽及药物用途
WO2022223007A1 (zh) * 2021-04-23 2022-10-27 中国人民解放军军事科学院军事医学研究院 抗病毒多肽化合物
EP4414377A4 (en) * 2022-02-21 2025-04-09 Youcare Pharmaceutical Group Co., Ltd. Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof
CN115724919B (zh) * 2022-11-11 2023-06-27 中国医学科学院病原生物学研究所 强效抑制艾滋病病毒及其耐药毒株的新型膜融合抑制剂及其药物用途

Also Published As

Publication number Publication date
KR20250109218A (ko) 2025-07-16
AU2023378464A1 (en) 2025-06-19
WO2024099428A1 (zh) 2024-05-16
JP2025537298A (ja) 2025-11-14
EP4617282A1 (en) 2025-09-17
CN115724919A (zh) 2023-03-03
CN115724919B (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
CL2025001381A1 (es) Inhibidor de la fusión de membranas para inhibir virus del sida y su uso farmacéutico.
CO2022010098A2 (es) Inhibidores de proteínas kras mutantes
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY28250A1 (es) Composiciones farmacéuticas para inhibidores de la proteasa del virus de la hepatitis c
UY27650A1 (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
MX2021016149A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
SA521421645B1 (ar) بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30
CO2022006965A2 (es) Inhibidores de egfr
CO2023005726A2 (es) Formulación sólida
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
DOP2021000129A (es) Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vih
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
MX2024012240A (es) Composiciones de bacillus y usos de las mismas
CO2024003094A2 (es) Compuesto imidazocíclico y aplicación del mismo
CO2022001218A2 (es) Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CL2008001537A1 (es) Compuestos heterociclo derivados de 1h-pirimidin-2,4-diona, dihidro-pirimidin-2,4-diona e imidazol-2,4-diona, inhibidores no nucleosidos de la transcriptasa inversa (nnrti) del vih-1; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por vih, sida o arc.
PE20130529A1 (es) Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico
UY38315A (es) Composición que comprende inhibidor de la alfa-1 proteinasa altamente concentrado y procedimiento para la obtención de la misma
DOP2021000028A (es) Formulaciones de dendrímeros